Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/180217
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Seymour, John F. | es_ES |
dc.contributor.author | Döhner, Hartmut | es_ES |
dc.contributor.author | Butrym, Aleksandra | es_ES |
dc.contributor.author | Wierzbowska, Agnieszka | es_ES |
dc.contributor.author | Selleslag, Dominik | es_ES |
dc.contributor.author | Jang, Jun Ho | es_ES |
dc.contributor.author | Kumar, Rajat | es_ES |
dc.contributor.author | Cavenagh, James | es_ES |
dc.contributor.author | Schuh, Andre C. | es_ES |
dc.contributor.author | Candoni, Anna | es_ES |
dc.contributor.author | Récher, Christian | es_ES |
dc.contributor.author | Sandhu, Irwindeep | es_ES |
dc.contributor.author | Bernal del Castillo, Teresa | es_ES |
dc.contributor.author | Al-Ali, Haifa Kathrin | es_ES |
dc.contributor.author | Falantes-González, José Francisco | es_ES |
dc.contributor.author | Stone, Richard M. | es_ES |
dc.contributor.author | Minden, Mark D. | es_ES |
dc.contributor.author | Weaver, Jerry | es_ES |
dc.contributor.author | Songer, Steve | es_ES |
dc.contributor.author | Beach, C. L. | es_ES |
dc.contributor.author | Dombret, Hervé | es_ES |
dc.date.accessioned | 2019-04-16T12:31:32Z | - |
dc.date.available | 2019-04-16T12:31:32Z | - |
dc.date.issued | 2017-12-14 | - |
dc.identifier.citation | BMC Cancer 17: 852 (2017) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/180217 | - |
dc.description.abstract | [Background] Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. | es_ES |
dc.description.abstract | [Methods] We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65–74 years or ≥75 years). The same analyses were used to compare azacitidine with low-dose cytarabine in patients who had been preselected to low-dose cytarabine before they were randomized to receive azacitidine or CCR (ie, low-dose cytarabine). | es_ES |
dc.description.abstract | [Results] Median overall survival was significantly prolonged with azacitidine (n = 129) versus CCR (n = 133): 8.9 versus 4.9 months (hazard ratio 0.74, [95%CI 0.57, 0.97]). Among patients with intermediate-risk cytogenetics, median overall survival with azacitidine was 16.4 months, and with CCR was 8.9 months (hazard ratio 0.73 [95%CI 0.48, 1.10]). Median overall survival was significantly improved for patients ages 65–74 years treated with azacitidine compared with those who received CCR (14.2 versus 7.3 months, respectively; hazard ratio 0.64 [95%CI 0.42, 0.97]). Within the subgroup of patients preselected to low-dose cytarabine before randomization, median overall survival with azacitidine was 9.5 months versus 4.6 months with low-dose cytarabine (hazard ratio 0.77 [95%CI 0.55, 1.09]). Within the low-dose cytarabine preselection group, patients with intermediate-risk cytogenetics who received azacitidine had a median overall survival of 14.1 months versus 6.4 months with low-dose cytarabine, and patients aged 65–74 years had median survival of 14.9 months versus 5.2 months, respectively. Overall response rates were similar with azacitidine and CCR (24.8% and 17.3%, respectively), but higher with azacitidine versus low-dose cytarabine (27.2% and 13.9%). Adverse events were generally comparable between the treatment arms. | es_ES |
dc.description.abstract | [Conclusions] Azacitidine may be the preferred treatment for patients with AML-MRC who are not candidates for intensive chemotherapy, particularly patients ages 65–74 years and those with intermediate-risk cytogenetics. | es_ES |
dc.description.abstract | [Trial registration] This study was registered at clinicalTrials.gov on February 16, 2010 (NCT01074047). | es_ES |
dc.description.sponsorship | This study was funded by Celgene Corporation. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | Azacitidine | es_ES |
dc.subject | Low-dose cytarabine | es_ES |
dc.subject | Acute myeloid leukemia | es_ES |
dc.subject | AML | es_ES |
dc.subject | Myelodysplasia-related changes | es_ES |
dc.subject | AML‐MRC | es_ES |
dc.subject | Induction chemotherapy | es_ES |
dc.subject | Response | es_ES |
dc.subject | Survival | es_ES |
dc.title | Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1186/s12885-017-3803-6 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s12885-017-3803-6 | es_ES |
dc.identifier.e-issn | 1471-2407 | - |
dc.rights.license | http://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Celgene | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/100006436 | es_ES |
dc.identifier.pmid | 29241450 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | artículo | - |
item.languageiso639-1 | en | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.cerifentitytype | Publications | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
myeloid_leukaemia.pdf | 1,85 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
26
checked on 18-may-2024
SCOPUSTM
Citations
49
checked on 14-may-2024
WEB OF SCIENCETM
Citations
44
checked on 23-feb-2024
Page view(s)
194
checked on 19-may-2024
Download(s)
145
checked on 19-may-2024